Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 12/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.34 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22353810 | 0.84 | CCR3 (0.37) | L3MBTL1 | |
| SCHEMBL22352815 | 0.81 | NR1H4 (0.42) | — | |
| SCHEMBL22354095 | 0.80 | DRD4 (0.44) | DRD4DRD3EGFRL3MBTL1KCNJ6 | |
| SCHEMBL24258778 | 0.72 | CNR1 (0.32) | — | |
| SCHEMBL22353911 | 0.71 | ALDH1A1 (0.37) | DRD4DRD3EGFRL3MBTL1 | |
| SCHEMBL22347270 | 0.71 | NR1H4 (0.41) | DRD4DRD3EGFRKCNJ6KCNJ5 | |
| SCHEMBL22353788 | 0.70 | MTNR1A (0.38) | DRD4DRD3EGFRL3MBTL1 | |
| SCHEMBL24258959 | 0.70 | NR1H4 (0.34) | — | |
| SCHEMBL24258835 | 0.67 | PSMB8 (0.31) | — | |
| SCHEMBL22353782 | 0.66 | MIF (0.39) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | DRD4 4592/4885DRD3 3522/4885EGFR 249/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | DRD4 4592/4885DRD3 3522/4885EGFR 249/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | DRD4 4592/4885DRD3 3522/4885EGFR 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.